Join us at the ASGCT Annual Meeting 2025

Driving advanced therapies to the clinic

Join us to learn about how IDT’s CRISPR genome editing solution can help you rapidly move from the lab to therapeutic clinical applications.

Our CRISPR product and services portfolio includes a comprehensive set of tools, reagents, and services for your genome editing, including discovery, preclinical research, and clinical applications.

Register for the Conference

Meet with our experts at ASGCT 2025

We’re excited to meet you at ASGCT 2025 and discuss how IDT can support your cell and gene therapy development from research to clinical translational and beyond.

Fill out the form below to enter your information and be contacted by our sales team to set up an appointment.

Schedule a Meeting

Scientific symposium

A Platform Approach to Gene Editing-Based Therapeutics
Danaher and Innovative Genomic Institute

Thursday, May 15, 2025
Rooms 391-392

IDT is proud to be a part of Danaher. Together, we combine our capabilities to accelerate the real-life impact of tomorrow’s science and technology.

Danaher Corporation and the Innovative Genomics Institute (IGI) are collaborating to develop gene-editing therapies for rare and other diseases, with a goal of creating a new model for future development of a wide range of genomic medicines.

The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to permanently address hundreds of diseases with a unified research, development and regulatory approach.

Danaher Life Sciences Group is honored to sponsor this first publicly held talk to provide insight into the studies and key findings by IGI team.

Register Now

Posters

Improved prediction and activation of homology-directed repair in translational ex-vivo systems

Speaker: Rolf Turk, Senior Director, Innovation Programs
Poster session: Tuesday poster reception
Date: May 13, 2025
Time: 6:00 PM–7:30 PM
Room: Poster Hall 12

CRISPR library design solutions for efficient gene knockout screening

Speaker: Javier Alejandro Gomez, Research Scientist III
Poster session: Tuesday poster reception
Date: May 13, 2025
Time: 6:00-7:30 PM
Room: Poster Hall 12

Evolving solutions for effective genotoxicity assessment in CRISPR-Cas gene editing

Speaker: Gavin Kurgan, Bioinformatics Applications Development Manager
Poster session: Wednesday session
Date: May 14, 2025
Time: 5:30-7:00 PM
Room: Poster Hall 12

Engineering an improved inhibitor of 53BP1 to enhance HDR efficiency

Speaker: Joe O’Brian, Research Scientist III
Poster session: Thursday Poster Reception
Date: May 15, 2025
Time: 5:30–7:00 PM
Room: Poster Hall 12

Engineering SpCas9 to be compatible with sgRNAs with shorter constant regions

Speaker: Steve Glenn, Staff Scientist
Poster session: Thursday poster reception
Date: May 15, 2025
Time: 5:30-7:00 PM
Room: Poster Hall 12

Standardized methods in iPSC for CRISPR-based editing and homology directed repair (HDR)

Speaker: Karthik Murugan, Research Scientist III
Poster session: Thursday poster reception
Date: May 15, 2025
Time: 5:30-7:00 PM
Room: Poster Hall 12

Scientific collaborations

Comprehensive on- and off-target validation using integrated rhAmpSeq™ and targeted DNA resequencing single-cell technology for gene editing applications

Company: MissionBio
Speaker: Shu Wang
Poster session: Thursday poster reception
Date: May 15, 2025
Time: 5:30-7:00 PM
Poster number: 1634

Featured products

CRISPR Genome Editing Solutions

Therapeutic applications

• CRISPR CGMP gRNA manufacturing

  For customers looking to accelerate their CRISPR genome editing from discovery to clinical trials, our Engineering Run and full CGMP guide RNA (gRNA) manufacturing services offer a streamlined and regulatory-compliant solution. Backed by comprehensive documentation, our CGMP gRNAs can simplify regulatory filings, offering a less burdensome path to clinical success. Get a free consultation with one of our clinical development leaders.

• CGMP CRISPR nucleases

  For those applying gene editing to investigate and treat genetic and inherited diseases, these nucleases provide an accelerated path to the clinic by offering the same product manufactured at research grade and full CGMP, supported by the quality documentation necessary for regulatory filings.

• CRISPR Off-target Analysis Service

  Leverage IDT’s deep expertise in CRISPR off-target analysis to deliver unparalleled off-target editing analytical services for your CRISPR projects from research to clinic, including IND support.

Research applications

Gene knock-out studies (non-homologous end joining, NHEJ)

• Alt-R™ CRISPR-Cas9 System

  Efficient CRISPR reagents based on the commonly used Streptococcus pyogenes Cas9 system for lipofection or electroporation experiments. Protospacer adjacent motif (PAM) = NGG.

• Alt-R CRISPR-Cas12a (Cpf1) System

  For additional target sites or for targeting AT-rich regions, use the CRISPR-Cas12a system in electroporation experiments. Protospacer adjacent motif (PAM) = TTTV. The Alt-R Cas12a (Cpf1) Ultra also can recognize many TTTT PAM sites in addition to TTTV motifs, increasing target range for genome editing studies.

Gene knock-in studies (homology-directed repair, HDR)

• Alt-R HDR Design Tool*

  A complete solution for high HDR rates based on wet bench testing and customer validation. It provides exceptional flexibility for seamless HDR design for your insertion, deletion, SNP, and amino acid mutation studies. Alt-R HDR Donor Oligos are enhanced Ultramer™ DNA oligos (up to 200 bases) specifically built for HDR. Alt-R HDR Donor Blocks are ideal for HDR-mediated insertions larger than 120 bases.

  *Available for wild type/HiFi Cas9 or nickase designs.

Genome editing analysis

• rhAmpSeq™ CRISPR Analysis System

  An end-to-end solution to design, deploy, and analyze next generation sequencing data for on- and off-target interrogation after your CRISPR experiment.

• Alt-R Genome Editing Detection Kit

  A T7 endonuclease I (T7EI) mismatch cleavage assay for detection of on-target editing, known off-target events, and estimation of genome editing efficiency in cultured cells.